Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment
Open Access
- 27 February 2021
- Vol. 26 (5), 1294
- https://doi.org/10.3390/molecules26051294
Abstract
Cisplatin-based treatment is the standard of care therapy for urothelial carcinomas. However, complex cisplatin resistance mechanisms limit the success of this approach. Both apoptosis and autophagy have been shown to contribute to this resistance. Prodigiosin, a secondary metabolite from various bacteria, exerts different biological activities including the modulation of these two cellular stress response pathways. We analyzed the effect of prodigiosin on protein levels of different autophagy- and apoptosis-related proteins in cisplatin-sensitive and -resistant urothelial carcinoma cells (UCCs). Furthermore, we investigated the effect on cell viability of prodigiosin alone or in combination with cisplatin. We made use of four different pairs of cisplatin-sensitive and -resistant UCCs. We found that prodigiosin blocked autophagy in UCCs and re-sensitized cisplatin-resistant cells to apoptotic cell death. Furthermore, we found that prodigiosin is a potent anticancer agent with nanomolar IC50 values in all tested UCCs. In combination studies, we observed that prodigiosin sensitized both cisplatin-sensitive and -resistant urothelial carcinoma cell lines to cisplatin treatment with synergistic effects in most tested cell lines. These effects of prodigiosin are at least partially mediated by altering lysosomal function, since we detected reduced activities of cathepsin B and L. We propose that prodigiosin is a promising candidate for the therapy of cisplatin-resistant urothelial carcinomas, either as a single agent or in combinatory therapeutic approaches.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (STO 864/5-1, STO 864/6-1, GK 2158)
- Bundesministerium für Bildung und Forschung (031B0918A – project ‘AutoBiotech’)
This publication has 57 references indexed in Scilit:
- The global burden of urinary bladder cancer: an updateWorld Journal of Urology, 2019
- New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to MicroenvironmentInternational Journal of Molecular Sciences, 2019
- Management of metastatic bladder cancerCancer Treatment Reviews, 2019
- High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancerCancer Management and Research, 2019
- Epidemiology, aetiology and screening of bladder cancerTranslational Andrology and Urology, 2019
- Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder CancerEuropean Urology, 2016
- New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinantsDrug Resistance Updates, 2015
- Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic ChangesPharmacological Reviews, 2012
- Molecular mechanisms of cisplatin resistance in bladder cancerExpert Review of Anticancer Therapy, 2012
- Cisplatin: From DNA damage to cancer chemotherapyProgress in Nucleic Acid Research and Molecular Biology, 2001